Company profile
Protagonist Therapeutics, Inc.
NASDAQ: PTGX · Healthcare · Biotechnology
#443 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
57CFH 57DQ 65GM 32SS 69
v0.1 · 65/100 weight · provisional
↑ Altman-Z, balance-sheet leverage · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$74.1M
Rev growth YoY (TTM)
-64.4%
Net income (FY)
-$130.1M
Employees
132
as of 2026-08-06
Market cap
$8.8B
as of 2026-08-06
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$46.0M$46.0M2025
Net income-$130.1M-$130.1M2025
Operating income-$158.1M-$158.1M2025
Total assets$668.2M$668.2M2025
Liabilities$53.5M$53.5M2025
Equity$614.7M$614.7M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY21
FY21
FY21
FY22
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2024
By product
Development Services100%
By geography
Not disclosed.
The read
What is Protagonist Therapeutics, Inc.’s revenue?
Protagonist Therapeutics, Inc. booked $46.0M in FY2025 revenue, contracting 89% year over year — slower than 90% of Healthcare companies we track, at a -282.8% net margin.
Peers · Healthcare
Gossamer Bio, Inc.24DShoulder Innovations, Inc.42DEvome Medical Technologies Inc.——Septerna Inc51DTriSalus Life Sciences, Inc.44DFennec Pharmaceuticals Inc.61CNeighbors
Alameda →Key facts
CEODinesh V. Patel
SectorHealthcare
IndustryBiotechnology
HeadquartersNewark, CA
ExchangeNASDAQ: PTGX
Employees132
IPO date2016-08-11
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.